All In Biotech

Drug Trial Radar · NCT07367971

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Jan 23, 2026

Primary completion

Aug 19, 2026

Study completion Aug 19, 2026

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Jan 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Conditions

  • Gout Chronic
  • Gout
  • DDI (Drug-Drug Interaction)

Interventions

  • ABP-671 plus allopurinolDrug

    All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol; Period 2 (Day 1-7): Allopurinol Plus ABP-671; Period 3 (Day 1-7): ABP-671;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration (Cmax) of allopurinolTime frame: Base line, through Day1, Day 7,Day8,D14,D15,D21
  2. Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinolTime frame: Base line, through Day1, Day 7,Day8,D14,D15,D21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wakefield Clinical Research

    Cary, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.